Syngene International, a subsidiary of Indian biotechnology major, Biocon and
Bristol-Myers Squibb Company has inaugurated its fully dedicated research and
development (R&D) facility for Bristol-Myers Squibb in Biocon Park, Bangalore.
The 20,000 sq. ft R&D facility at Biocon Park is devoted to help advance
Bristol-Myers Squibb's work in discovery and early drug development, and is
currently occupied by 270 researchers. The construction of the facility was
started in March 2007 after Bristol Myers Squibb and Biocon entered into an
agreement to develop integrated drug discovery and development capabilities at
Syngene.